ArticleThe American journal of tropical medicine and hygiene2025
An O-Specific Polysaccharide Shigella flexneri 3a Conjugate Vaccine is Immunogenic and Protective against Virulent Keratoconjunctival Challenge in Guinea Pigs.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Shigella infection is a major cause of diarrhea, cognitive and physical stunting, and death in young children in resource-limited settings. A vaccine that is protective against shigellosis is needed. Immune responses that target the O-specific polysaccharide (OSP) of Shigella spp. are protective against shigellosis. We previously reported the development and evaluation of a conjugate vaccine targeting Shigella flexneri (S. flexneri) 3a in mice. Here, we report the evaluation of this vaccine (Shigella conjugate vaccine S. flexneri 3a OSP conjugated to a 52 kiloDalton recombinant fragment of the tetanus toxin heavy chain [SCV-Sf3a OSP:rTTHc]) in a second animal model: the guinea pig. This vaccine induced prominent OSP-, lipopolysaccharide-, and rTTHc-specific Immunoglobulin (Ig)G, IgA, and IgM responses in the sera of vaccinated animals. Shigella conjugate vaccine S. flexneri 3a also induced serum bactericidal functional antibody responses, and vaccinated guinea pigs were protected against a virulent strain of keratoconjunctival challenge in the standard Shigella Sereny assay. These results support the further development of SCV-Sf3a OSP:rTTHc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.